Abstract
This population-based study was conducted to ascertain metastasis patterns and survival outcomes of esophageal adenocarcinoma (EAC) patients with distant metastasis (DM) in stage IVB. Elderly patients with multiple-site metastasis exhibited the worst overall survival (OS) and cancer-specific survival (CSS) among all populations, and patients with bone-only metastasis had the worst OS and CSS among single-organ metastasis populations. Active treatment is beneficial for elderly EAC patients with DM in stage IVB, especially chemotherapy. This study also shows that more than one-third of the patients had not received any therapy.
Introduction
Esophageal adenocarcinoma (EAC) is an aggressive malignancy frequently diagnosed at advanced stages in older adults. In Stage IVB, characterized by distant metastasis, clinical management typically shifts from curative intent to palliative care. However, there is a significant knowledge gap regarding metastasis patterns and treatment outcomes specifically in the elderly (age 70+). Clinicians often face the challenge of balancing aggressive treatment benefits against patient frailty. This study aims to provide a data-driven foundation for clinical decision-making by analyzing metastatic spread and the impact of various treatment modalities in this demographic.
Methodology
The researchers performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) 18-Registry database. The study focused on 855 elderly EAC patients diagnosed between 2010 and 2015, a period chosen because SEER began recording site-specific metastasis data in 2010.
Patients were categorized based on the site of distant metastasis (DM):
- Single-organ groups: Bone-only, brain-only, lung-only, or liver-only.
- Multiple-site group: Metastasis in two or more of these organs.
Prognostic factors were identified using Univariate and Multivariate Cox regression, while survival outcomes—Overall Survival (OS) and Cancer-Specific Survival (CSS)—were visualized using Kaplan-Meier analysis.
Results and Discussion
Metastasis Patterns
The liver was identified as the most common site of single-organ spread (40.9%), followed by the lungs (12.7%) and bone (12.0%). While multiple-site metastasis predictably carried the worst prognosis (Median Survival Time [MST] of 2 months), bone-only metastasis was the deadliest among single-organ groups (MST of 3 months). This "bone-only paradox" may be attributed to complications such as hypercalcemia and rapid progression associated with bone marrow involvement.
Treatment Efficacy and the "Treatment Gap"
A significant finding was that 35.9% of patients received no treatment, likely due to clinical bias regarding elderly frailty or patient refusal of aggressive care. However, the data strongly suggests that active treatment—particularly chemotherapy—significantly improves survival.
Multivariate analysis revealed that the risk of death for untreated patients was more than four times higher (HR: 4.782) than for those receiving combined aggressive therapy (Surgery, Radiotherapy, and Chemotherapy). Chemotherapy emerged as the most beneficial independent prognostic factor in this elderly cohort.
Conclusion and Limitations
Active treatment, especially chemotherapy, provides a clear survival benefit for elderly Stage IVB EAC patients. Despite this, a large portion of the population remains untreated.
The study's limitations include the SEER database's lack of specific chemotherapy details (dosages, drug types) and patient performance status (comorbidities). As a retrospective study, it demonstrates correlation rather than definitive causation. Future research should focus on multimodal therapies tailored for the elderly to maximize survival while preserving quality of life.
Summary updated